Brokerages expect Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Rating) to report earnings of ($0.20) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Gemini Therapeutics’ earnings. Gemini Therapeutics reported earnings per share of ($0.59) during the same quarter last year, which would indicate a positive year over year growth rate of 66.1%. The firm is expected to issue its next earnings results on Monday, January 1st.
On average, analysts expect that Gemini Therapeutics will report full year earnings of ($0.60) per share for the current fiscal year, with EPS estimates ranging from ($0.78) to ($0.32). For the next fiscal year, analysts anticipate that the business will report earnings of ($0.48) per share, with EPS estimates ranging from ($0.87) to ($0.26). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that that provide coverage for Gemini Therapeutics.
Gemini Therapeutics (NASDAQ:GMTX – Get Rating) last posted its quarterly earnings results on Thursday, March 10th. The company reported ($0.41) earnings per share for the quarter, beating the consensus estimate of ($0.50) by $0.09.
GMTX has been the topic of a number of research analyst reports. SVB Leerink lowered Gemini Therapeutics from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $10.00 to $2.00 in a research note on Thursday, March 3rd. Zacks Investment Research raised Gemini Therapeutics from a “hold” rating to a “buy” rating and set a $1.50 target price on the stock in a report on Monday, March 7th. Jefferies Financial Group downgraded Gemini Therapeutics from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $23.00 to $1.50 in a report on Tuesday, March 1st. Finally, HC Wainwright downgraded Gemini Therapeutics from a “buy” rating to a “neutral” rating and cut their price target for the company from $5.00 to $2.00 in a research note on Friday, March 11th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, Gemini Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $6.00.
In other Gemini Therapeutics news, major shareholder Braden Michael Leonard bought 191,769 shares of the company’s stock in a transaction that occurred on Wednesday, April 13th. The shares were purchased at an average price of $1.52 per share, with a total value of $291,488.88. Following the completion of the acquisition, the insider now directly owns 5,000,000 shares of the company’s stock, valued at approximately $7,600,000. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 12.90% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in the business. Morgan Stanley boosted its stake in shares of Gemini Therapeutics by 22.4% during the second quarter. Morgan Stanley now owns 29,976 shares of the company’s stock valued at $194,000 after acquiring an additional 5,480 shares during the last quarter. BlackRock Inc. boosted its stake in shares of Gemini Therapeutics by 0.6% in the fourth quarter. BlackRock Inc. now owns 1,256,373 shares of the company’s stock valued at $3,657,000 after purchasing an additional 7,246 shares during the period. Walleye Capital LLC boosted its stake in Gemini Therapeutics by 43.1% during the 4th quarter. Walleye Capital LLC now owns 25,979 shares of the company’s stock valued at $76,000 after acquiring an additional 7,830 shares during the last quarter. Bank of America Corp DE boosted its stake in Gemini Therapeutics by 83.7% during the 4th quarter. Bank of America Corp DE now owns 20,761 shares of the company’s stock valued at $61,000 after acquiring an additional 9,461 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its position in shares of Gemini Therapeutics by 16.8% in the 3rd quarter. Bank of New York Mellon Corp now owns 73,059 shares of the company’s stock worth $295,000 after buying an additional 10,504 shares during the last quarter. Hedge funds and other institutional investors own 58.97% of the company’s stock.
Shares of NASDAQ GMTX opened at $1.49 on Friday. The stock’s 50 day moving average price is $1.48 and its 200-day moving average price is $2.37. Gemini Therapeutics has a twelve month low of $1.16 and a twelve month high of $12.95. The company has a market capitalization of $64.38 million, a PE ratio of -0.82 and a beta of 1.46.
Gemini Therapeutics Company Profile (Get Rating)
Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
Featured Stories
Get a free copy of the Zacks research report on Gemini Therapeutics (GMTX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Gemini Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Gemini Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.
Read More: Zacks: Analysts Anticipate Gemini Therapeutics, Inc. (NASDAQ:GMTX) Will Post Earnings of